[go: up one dir, main page]

WO2016014799A9 - Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy - Google Patents

Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy Download PDF

Info

Publication number
WO2016014799A9
WO2016014799A9 PCT/US2015/041738 US2015041738W WO2016014799A9 WO 2016014799 A9 WO2016014799 A9 WO 2016014799A9 US 2015041738 W US2015041738 W US 2015041738W WO 2016014799 A9 WO2016014799 A9 WO 2016014799A9
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
epidermal growth
egf
blockade
cancer immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/041738
Other languages
French (fr)
Other versions
WO2016014799A1 (en
Inventor
George Weiner
Mohammed Milhem
Amani MAKKOUK
Zuhair K. BALLAS
Lyse NORIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF
Publication of WO2016014799A1 publication Critical patent/WO2016014799A1/en
Publication of WO2016014799A9 publication Critical patent/WO2016014799A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are methods, compositions, kits, and systems for diagnosing and/or treating a patient via immunotherapy. The diagnostic methods including detecting epidermal growth factor (EGF) and administering to the patient a therapeutic antibody that binds to a cell surface receptor of a regulatory T cell (Treg) based on the detected EGF. The treatment methods include administering EGF or an agonist of the EGF receptor and administering the therapeutic antibody that binds to a cell surface receptor of a Treg.
PCT/US2015/041738 2014-07-23 2015-07-23 Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy Ceased WO2016014799A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028109P 2014-07-23 2014-07-23
US62/028,109 2014-07-23

Publications (2)

Publication Number Publication Date
WO2016014799A1 WO2016014799A1 (en) 2016-01-28
WO2016014799A9 true WO2016014799A9 (en) 2016-02-25

Family

ID=55163761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/041738 Ceased WO2016014799A1 (en) 2014-07-23 2015-07-23 Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy

Country Status (1)

Country Link
WO (1) WO2016014799A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035037B1 (en) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN108368170B (en) 2015-07-13 2022-04-15 西托姆克斯治疗公司 Anti-PD-1 antibody, activatable anti-PD-1 antibody and method of use
MX2018003689A (en) 2015-09-29 2018-04-30 Celgene Corp Pd-1 binding proteins and methods of use thereof.
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
WO2018187740A1 (en) * 2017-04-07 2018-10-11 Shasqi, Inc. Bioorthogonal compositions

Also Published As

Publication number Publication date
WO2016014799A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX2020008882A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
MX2021008053A (en) Methods for monitoring and treating cancer.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2016014799A9 (en) Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
MX2018010473A (en) Combination therapy with anti-cd73 antibodies.
GEP20227419B (en) Pd-1-binding molecules and methods of use thereof
MX2022006075A (en) Therapeutic and diagnostic methods for cancer.
MX376663B (en) Antibodies against FC receptor-like 5 (FCRH5).
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
HK1244681A1 (en) Therapeutic combinations and methods for treating neoplasia
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
MX2016014647A (en) Ox40l fusion proteins and uses thereof.
PH12016501366A1 (en) Novel anti-baff antibodies
BR112014018592A2 (en) composition and method for the diagnosis and treatment of diseases associated with neuronal degeneration
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
SG10201907501QA (en) Antibodies and assays for detection of folate receptor 1
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
MX2020009037A (en) B7-h4 antibodies and methods of use thereof.
MX2018012493A (en) Methods for monitoring and treating cancer.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
WO2015200828A8 (en) Conjugates for immunotherapy
BR112016002401A8 (en) METHODS FOR REDUCING ASTHMA EXACERBATION RATES USING BENRALIZUMAB
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824802

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824802

Country of ref document: EP

Kind code of ref document: A1